| Revenue Growth FY26 | 13.7%Organic |
|---|---|
| Market Cap | ₹11,373 CrMid-cap |
| Revenue TTM | ₹1,646 CrAnnual Operating |
| RSI | 73.49Overbought |
Key highlights
- Organic revenue grew by 13.7% in FY26, surpassing the management's upper guidance end of 13%
- EBITDA margins expanded by 140 basis points to 25.9%, with a long-term target of 27-28% by FY28
- Volume-led growth stood at 9.3%, complemented by a 5% improvement in realization and test mix
- Specialty testing grew by 17% and the True Health wellness segment grew by 20% in Q4FY26
- B2C contribution increased to 60% of total revenue, reflecting a shift toward retail consumer focus
- Plan to launch 100 'mini-hubs' over three years, combining pathology with basic radiology services
Financial Performance and Margin Expansion
Metropolis Healthcare delivered a robust financial performance for the fiscal year 2026, with operating revenue reaching ₹1,646 crore, marking a 24% year-on-year increase. The company's net profit for the year stood at ₹190 crore, a 31% growth over the previous fiscal. Growth was primarily volume-driven, with patient volumes increasing by 9.3%.
Despite not taking any price hikes in the fourth quarter due to GST-related considerations, the company improved its realization by 5% through a better product mix. EBITDA margins expanded to 25.9%, supported by disciplined cost management and the successful integration of recent acquisitions.
Strategic Pivot Toward Productivity
Management indicated a clear transition in its business model, moving away from the aggressive laboratory rollout phase of previous years. The new strategy focuses on 'throughput-led productivity,' where the objective is to maximize the utilization of the existing network of 212 labs. The company intends to strengthen its footprint by adding 1,500 new collection centers, aiming for a lab-to-center ratio of 1:35 over the next three years.
This optimization of the hub-and-spoke model is expected to drive the group's EBITDA margins toward the 27-28% range by FY28.
Expansion via Mini-Hubs and Specialized Testing
- Rollout of 100 'mini-hubs' planned to offer integrated pathology and basic radiology services like ECG and X-ray
- Genomics identified as a key strategic pillar, supported by specialized CAP-accredited labs in Mumbai and Delhi
- True Health wellness segment now contributes 19% of total revenue, growing at 21% annually
- Digital channels, including the Metropolis app and website, now contribute 25% of total revenue
- North India business contribution increased to 17% of total revenue, up from mid-single digits previously
Management Outlook
Over the next three years, the vision is to grow at a faster pace of 14 to 15% in revenue. Organic revenues will come primarily via patient volume, RPP growth, and price increases.
Sector Dynamics and Competitive Position
The diagnostic industry in India is witnessing a structural shift from unorganized to organized players as consumers increasingly prioritize quality standards and scientific expertise. Metropolis management noted that while competition from online discount-led platforms remains, the company's focus on specialty testing and doctor-led trust provides a significant moat. The rising contribution of high-end clinical tests in fields like oncology and neurology is expected to sustain realization growth.
The company maintains a strong balance sheet with a Piotroski score of 8, indicating robust financial health as it seeks strategic M&A opportunities.
What to Watch
- Execution of the 'mini-hub' rollout and its impact on the average revenue per patient
- Achievement of the 27-28% EBITDA margin target by FY28 through operating leverage
- Progress in the expansion of the North and East India business segments
- Potential price adjustments in future quarters following the price freeze in Q4FY26
“We do not see AI as a mere disruptor in pathology but an important enabler of productivity, service quality, customer engagement, and workflow efficiency.”
“The focus has clearly shifted from expand-led capex to throughput-led productivity. The priority today is not just to add more infrastructure but to get more output.”
| Share price | ₹548.55 |
|---|---|
| Market capitalisation | ₹11,372.97 Cr |
| Revenue (annual) | ₹1,645.85 Cr |
| Net profit (annual) | ₹190.02 Cr |
| Revenue (latest quarter) | ₹424.68 Cr+4.62% vs previous quarter |
| Net profit (latest quarter) | ₹50.90 Cr+23.00% vs previous quarter |
| P/E (TTM) | 59.85×Sector 63.52× |
| Promoter holding | 48.87%-0.01% QoQ |
| FII holding | 10.43%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Metropolis Healthcare Ltd announcing its Q4 and FY26 audited financial results and investor presentation. Market figures from a third-party data provider.
